You are here: Industry Insights > Upsher-Smith

News List

Dr Reddy’s announces closure of the transaction to divest Zembrace SymTouch and Tosymra to Upsher-Smith expresspharma
July 23, 2019
Dr Reddy’s Laboratories announced the closure of the transaction with Upsher-Smith Laboratories after the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement
Upsher-Smith to buy migraine drugs from Dr Reddy’s pharmaceutical-technology
June 19, 2019
Upsher-Smith Laboratories has signed a definitive asset purchase agreement to acquire neurology products from Dr Reddy’s Laboratories.
DRL to sell neurology branded products to Upsher-Smith Laboratories expressbpd
June 14, 2019
Dr Reddy’s would sell its US and select territory rights for ZEMBRACE SYMTOUCH and TOSYMRATM, which are commercialized through its wholly-owned subsidiary, Promius Pharma
Upsher-Smith Receives FDA Approval for Bumetanide Tablets, USP biospace
January 31, 2018
Upsher-Smith today announced that it has received U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg.
Japan's Sawai gets U.S. production with $1B deal for Upsher-Smith generics fiercepharma
June 08, 2017
Japan’s Sawai is following the path trod by other drugmakers with big plans for the U.S., establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.
Sawai Pays $1bn for Generics Biz of Upsher-Smith contractpharma
April 27, 2017
Acquisition marks a major expansion of Sawai's presence in the U.S. market
Upsher-Smith Launches Generic Clomipramine americanpharmaceuticalreview
March 23, 2017
Upsher-Smith Laboratories, Inc. has announced the U.S. launch of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 mg, the generic equivalent to Mallinckrodt Pharmaceuticals' Anafranil® (clomipramine hydrochloride) Capsules USP.